Evidence map›Paper›PMID 32230868›Full record

ArticleGenes2020

The

Ludivine Raby, Pamela Völkel, Xuefen Le Bourhis, Pierre-Olivier Angrand

Open access · goldAbstract read
In one paragraph

Article in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ludivine RabyUniversity Lille, CNRS, Inserm, CHU Lille, Centre Oscar Lambret, UMR 9020 - UMR 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
Pamela VölkelUniversity Lille, CNRS, Inserm, CHU Lille, Centre Oscar Lambret, UMR 9020 - UMR 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
Xuefen Le BourhisUniversity Lille, CNRS, Inserm, CHU Lille, Centre Oscar Lambret, UMR 9020 - UMR 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
Pierre-Olivier AngrandUniversity Lille, CNRS, Inserm, CHU Lille, Centre Oscar Lambret, UMR 9020 - UMR 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Polycomb Repressive Complex 1 (PRC1) is a chromatin-associated protein complex involved in transcriptional repression of hundreds of genes controlling development and differentiation processes, but also involved in cancer and stem cell biology. Within the canonical PRC1, members of Pc/CBX protein family are responsible for the targeting of the complex to specific gene loci. In mammals, the Pc/CBX protein family is composed of five members generating, through mutual exclusion, different PRC1 complexes with potentially distinct cellular functions. Here, we performed a global analysis of the

Indexed as

Gene DuplicationGene Expression Regulation, DevelopmentalAnimalsCell DifferentiationCell NucleusChromatinFishesFish ProteinsGenomePolycomb-Group ProteinsZebrafishChromatinFish ProteinsPolycomb-Group ProteinsCBXphylogenetic analysispolycomb group proteinsTeleost fisheszebrafish

Identifiers

PMID32230868
PMCPMC7230241
OpenAlexW3013840376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.